Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
Anna S KolodziejczakLea Guerrini-RousseauJulien Masliah PlanchonJonas EckerFlorian SeltMartin MynarekDenise ObrechtMartin SillRobert J AutryEric ZhaoSteffen HirschElsa AmouyalChristelle DufourOlivier AyraultJacob TorrejonSebastian M WaszakVijay RamsawamiVirve PentikainenHaci Ahmet DemirSteven C CliffordEd C SchwalbeLuca MassimiMatija SnuderlKristyn GalbraithMatthias A KarajannisKatherine HillBryan K LiMike WalshChristine L WhiteShelagh RedmondLoizou LoizosMarcus JakobUwe R KordesIrene SchmidJulia HauerClaudia BlattmannMaria FilippidouGianluca PiccoloWolfram ScheurlenAhmed FarragKerstin GrundChristian SutterTorsten PietschStephan FrankDenis M ScheweDavid MalkinMyriam Ben-ArushAstrid SehestedTai-Tong WongKuo-Sheng WuYen-Lin LiuFernando CarcellerSabine MuellerSchuyler StollerMichael D TaylorUri TaboriEric BouffetMarcel KoolFelix SahmAndreas von DeimlingAndrey KorshunovKatja von HoffChristian P KratzDominik SturmDavid T W JonesStefan RutkowskiCornelis M van TilburgOlaf WittGaëlle BougeardKristian W PajtlerStefan M PfisterFranck BourdeautTill MildePublished in: Neuro-oncology (2023)
LFS MB patients have a dismal prognosis. In the presented cohort use of RT significantly increased survival rates, whereas chemotherapy intensity did not influence their clinical outcome. Prospective collection of clinical data and development of novel treatments are required to improve the outcome of LFS MB patients.